Related Experiment Video
Updated: May 15, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple
Huiqiong Lin1, Iryna Kolosenko, Ann-Charlotte Björklund
1Department of Oncology-Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden.
Abstract:
The molecular chaperone Hsp90 is required to maintain the activity of many signaling proteins, including members of the JAK/STAT and the PI3K pathways. Inhibitors of Hsp90 (Hsp90-Is) demonstrated varying activity against multiple myeloma (MM) in clinical trials. We aimed to determine which signaling pathways that account for the differential sensitivity to the Hsp90-I 17DMAG on a panel of MM cell lines and freshly obtained MM cells. Three CD45(+) cell lines with an activated JAK/STAT3 pathway were sensitive to 17DMAG and underwent prominent apoptosis upon treatment, while the majority of CD45(-) cell lines, that were dependent on the activated PI3K pathway, were more resistant to the drug. Culturing the most resistant cell line, LP1, in the presence of IL-6 resulted in up-regulation of CD45 and pSTAT3, and sensitized to 17DMAG-induced apoptosis, primarily in the induced CD45(+) sub-population of cells. The high CD45 expressers among primary myeloma cells also expressed significantly higher levels of pSTAT3, as compared to the low CD45 expressers. Ex vivo treatment of primary myeloma cells with 17DMAG resulted in a stronger caspase3 activation in tumor samples with the prevalence of high CD45 expressers. STAT3 activity was efficiently inhibited by Hsp90-Is in both cell lines and primary cells suggesting an importance of STAT3 inactivation for the pro-apoptotic effects of HSP90-Is. Indeed, over-expression of STAT3C, a variant with an increased DNA binding activity, in U266 cells protected them from 17DMAG-induced cell death. The down-regulation of the STAT3 target gene Mcl-1 at both the mRNA and protein levels following 17DMAG treatment was significantly attenuated in STAT3C-expressing cells, and transient over-expression of Mcl-1 protected U266 cells from 17DMAG-induced cell death. The finding that CD45(+) MM cells with an IL-6-activated JAK/STAT3 pathway are particularly sensitive to Hsp90-Is as compared to the low CD45 expressers may provide a rational basis for selection of MM patients amenable to Hsp90-I treatment.
Insights
Hsp90 inhibitors like 17DMAG show differential activity in multiple myeloma (MM). CD45(+) MM cells with activated JAK/STAT3 pathways are sensitive, while CD45(-) cells with PI3K pathway activation are resistant.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Heat shock protein 90 (Hsp90) is crucial for signaling protein activity, including JAK/STAT and PI3K pathways.
- Hsp90 inhibitors (Hsp90-Is) have shown variable efficacy in multiple myeloma (MM) clinical trials.
Purpose of the Study:
- To investigate the signaling pathways responsible for differential sensitivity to the Hsp90 inhibitor 17DMAG in MM cell lines and primary cells.
- To identify biomarkers predicting response to Hsp90 inhibition in MM.
Main Methods:
- Treatment of MM cell lines and primary MM cells with 17DMAG.
- Analysis of JAK/STAT3 and PI3K pathway activation.
- Assessment of CD45 expression levels.
- Evaluation of apoptosis and caspase-3 activation.
- Over-expression of STAT3C and Mcl-1 to assess their role in drug resistance.
Main Results:
- CD45(+) MM cell lines with activated JAK/STAT3 were sensitive to 17DMAG, undergoing apoptosis.
- CD45(-) MM cell lines dependent on PI3K signaling were more resistant.
- IL-6 treatment induced CD45 and pSTAT3, sensitizing resistant cells to 17DMAG.
- Primary MM cells with high CD45 expression showed higher pSTAT3 and increased caspase-3 activation upon 17DMAG treatment.
- STAT3 inhibition was key to Hsp90-Is' pro-apoptotic effects, while STAT3C over-expression conferred resistance.
- Mcl-1 down-regulation by 17DMAG was attenuated in STAT3C-expressing cells.
Conclusions:
- CD45 expression and JAK/STAT3 pathway activation are key determinants of sensitivity to Hsp90 inhibitors in MM.
- Hsp90 inhibition targets the JAK/STAT3 pathway, leading to apoptosis in sensitive MM cells.
- High CD45 expression identifies MM patients likely to benefit from Hsp90-I therapy.
Related Concept Videos
The JAK-STAT Signaling Pathway
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
